Section Arrow
Quote
KZIA.NASDAQ
- Kazia Therapeutics Limited
Quotes are at least 15-min delayed:2026/01/09 09:42 EST
Regular Hours
Last
 7.05
+0.27 (+3.98%)
Day High 
7.08 
Prev. Close
6.78 
1-M High
17.1 
Volume 
1.29K 
Bid
6.57
Ask
7.1
Day Low
6.77 
Open
6.78 
1-M Low
5 
Market Cap 
76.86M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 6.58 
20-SMA 8.51 
50-SMA 8.88 
52-W High 17.4 
52-W Low 2.86 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-18.90/-0.83
Enterprise Value
76.86M
Balance Sheet
Book Value Per Share
-0.49
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
42.00K
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
IBIOiBio2.685+0.335+14.26%0.65PE
SLSSELLAS Life Sciences Group3.5218-0.3382-8.76%-- 
ARDXArdelyx7.64+0.64+9.14%-- 
ABSIAbsci Corp3.345-0.095-2.76%-- 
ALLOAllogene Therapeutics1.79+0.3+20.13%-- 
Industry overview quotes are at least 15 minutes delayed
Business Description
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.